Cyprium Therapeutics, a Fortress Biotech Partner Company, and Sentynl Therapeutics, a Wholly-owned Subsidiary of the Zydus Group, Sign Development and Asset Purchase Agreement for Cyprium Therapeutics’ Copper Histidinate Product Candidate for Treatment of Menkes Disease

Sentynl acquires CUTX-101, Copper Histidinate, for $20 million in upfront and regulatory milestone payments through NDA approval, as well as potential sales milestones plus royalties Cyprium will retain 100% ownership over any FDA priority review vouc…

Fortress Biotech to Participate in Three January 2021 Virtual Investor Conferences

NEW YORK, Jan. 05, 2021 (GLOBE NEWSWIRE) — Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative revenue-generating company focused on acquiring, developing and commercializing or monetizing promising biopharmaceutical products and product candidates cost-effectively, today announced that Lindsay A. Rosenwald, M.D., Chairman, President and Chief Executive Officer, will participate in three virtual investor conferences in January… Continue reading Fortress Biotech to Participate in Three January 2021 Virtual Investor Conferences

Fortress Biotech to Participate in Three January 2021 Virtual Investor Conferences

NEW YORK, Jan. 05, 2021 (GLOBE NEWSWIRE) — Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative revenue-generating company focused on acquiring, developing and commercializing or monetizing promising biopharmaceutical products and product candidates cost-effectively, today announced that Lindsay A. Rosenwald, M.D., Chairman, President and Chief Executive Officer, will participate in three virtual investor conferences in January… Continue reading Fortress Biotech to Participate in Three January 2021 Virtual Investor Conferences

Fortress Biotech to Participate in Three January 2021 Virtual Investor Conferences

NEW YORK, Jan. 05, 2021 (GLOBE NEWSWIRE) — Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative revenue-generating company focused on acquiring, developing and commercializing or monetizing promising biopharmaceutical products and product candidates cost-effectively, today announced that Lindsay A. Rosenwald, M.D., Chairman, President and Chief Executive Officer, will participate in three virtual investor conferences in January… Continue reading Fortress Biotech to Participate in Three January 2021 Virtual Investor Conferences

Fortress Biotech to Participate in Three January 2021 Virtual Investor Conferences

NEW YORK, Jan. 05, 2021 (GLOBE NEWSWIRE) — Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative revenue-generating company focused on acquiring, developing and commercializing or monetizing promising biopharmaceutical products and product candidates cost-effectively, today announced that Lindsay A. Rosenwald, M.D., Chairman, President and Chief Executive Officer, will participate in three virtual investor conferences in January… Continue reading Fortress Biotech to Participate in Three January 2021 Virtual Investor Conferences

Fortress Biotech to Participate in Three January 2021 Virtual Investor Conferences

NEW YORK, Jan. 05, 2021 (GLOBE NEWSWIRE) — Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative revenue-generating company focused on acquiring, developing and commercializing or monetizing promising biopharmaceutical products and product candidates cost-effectively, today announced that Lindsay A. Rosenwald, M.D., Chairman, President and Chief Executive Officer, will participate in three virtual investor conferences in January… Continue reading Fortress Biotech to Participate in Three January 2021 Virtual Investor Conferences

Fortress Biotech to Participate in Three January 2021 Virtual Investor Conferences

NEW YORK, Jan. 05, 2021 (GLOBE NEWSWIRE) — Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative revenue-generating company focused on acquiring, developing and commercializing or monetizing promising biopharmaceutical products and product candidates cost-effectively, today announced that Lindsay A. Rosenwald, M.D., Chairman, President and Chief Executive Officer, will participate in three virtual investor conferences in January… Continue reading Fortress Biotech to Participate in Three January 2021 Virtual Investor Conferences

Fortress Biotech Ranked in Deloitte’s Technology Fast 500™ for the Second Year in a Row

NEW YORK, Nov. 18, 2020 (GLOBE NEWSWIRE) — Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative revenue-generating company focused on acquiring, developing and commercializing or monetizing promising biopharmaceutical products and product candidates cost-effectively, today announced that it ranked number 135 in Deloitte’s 2020 Technology Fast 500™, an annual ranking of the fastest-growing North American companies… Continue reading Fortress Biotech Ranked in Deloitte’s Technology Fast 500™ for the Second Year in a Row

Fortress Biotech Reports Third Quarter 2020 Financial Results and Recent Corporate Highlights

Product revenue for the first nine months of 2020 increased 29% year-over-year to $30.8 million Rolling submission of the New Drug Application for CUTX-101 is expected to begin in the first quarter of 2021 and be completed by the end of the second quarter of 2021 NEW YORK, Nov. 09, 2020 (GLOBE NEWSWIRE) — Fortress… Continue reading Fortress Biotech Reports Third Quarter 2020 Financial Results and Recent Corporate Highlights